Relating neuronal nicotinic acetylcholine receptor subtypes defined by subunit composition and channel function. 2003

Qiang Nai, and J Michael McIntosh, and Joseph F Margiotta
Department of Anatomy and Neurobiology, Medical College of Ohio, Toledo, Ohio 43614, USA.

Neuronal nicotinic acetylcholine receptors (nAChRs) are widespread, diverse ion channels involved in synaptic signaling, addiction, and disease. Despite their importance, the relationship between native nAChR subunit composition and function remains poorly defined. Chick ciliary ganglion neurons express two major nAChR types: those recognized by alpha-bungarotoxin (alphaBgt), nearly all of which contain only alpha7 subunits (alpha7-nAChRs) and those insensitive to alphaBgt, which contain alpha3, alpha5, beta4, and, in some cases, beta2 subunits (alpha3*-nAChRs). We explored the relationship between nAChR composition and channel function using toxins recognizing alpha7 subunits (alphaBgt), and alpha3/beta4 (alpha-conotoxin-AuIB), or alpha3/beta2 (alpha-conotoxin-MII) subunit interfaces to perturb responses induced by nicotine, alpha7-, or alpha3-selective agonists (GTS-21 or epibatidine, respectively). Using these reagents, fast-decaying whole-cell current components were attributed solely to alpha7-nAChRs, and slow-decaying components mostly to alpha3*-nAChRs. In outside-out patches, nicotine activated brief 60- and 80-pS single nAChR channel events, and mixed-duration 25- and 40-pS nAChR events. Subsequently, 60- and 80-pS nAChR events and most brief 25- and 40-pS events were attributed to alpha7-nAChRs, and long 25- and 40-pS events to alpha3*-nAChRs. alpha3*-nAChRs lacking beta2 subunits seemed responsible for long 25 pS nAChR events, whereas those containing beta2 subunits mediated the long 40 pS nAChR events that dominate single-channel records. These results reveal greater functional heterogeneity for alpha7-nAChRs than previously expected and indicate that beta2 subunits contribute importantly to alpha3*-nAChR function. By linking structural to functional nAChR subtypes, the findings also illustrate a useful pharmacological strategy for selectively targeting nAChRs.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D009538 Nicotine Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. Nicotine Bitartrate,Nicotine Tartrate
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011978 Receptors, Nicotinic One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors. Nicotinic Acetylcholine Receptors,Nicotinic Receptors,Nicotinic Acetylcholine Receptor,Nicotinic Receptor,Acetylcholine Receptor, Nicotinic,Acetylcholine Receptors, Nicotinic,Receptor, Nicotinic,Receptor, Nicotinic Acetylcholine,Receptors, Nicotinic Acetylcholine
D002038 Bungarotoxins Neurotoxic proteins from the venom of the banded or Formosan krait (Bungarus multicinctus, an elapid snake). alpha-Bungarotoxin blocks nicotinic acetylcholine receptors and has been used to isolate and study them; beta- and gamma-bungarotoxins act presynaptically causing acetylcholine release and depletion. Both alpha and beta forms have been characterized, the alpha being similar to the large, long or Type II neurotoxins from other elapid venoms. alpha-Bungarotoxin,beta-Bungarotoxin,kappa-Bungarotoxin,alpha Bungarotoxin,beta Bungarotoxin,kappa Bungarotoxin
D002642 Chick Embryo The developmental entity of a fertilized chicken egg (ZYGOTE). The developmental process begins about 24 h before the egg is laid at the BLASTODISC, a small whitish spot on the surface of the EGG YOLK. After 21 days of incubation, the embryo is fully developed before hatching. Embryo, Chick,Chick Embryos,Embryos, Chick
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001597 Benzylidene Compounds Compounds which include a double-bonded carbon atom that is directly attached to a benzene ring. While this category is named after the highly reactive compound benzylidene, the compounds listed under it occur through a variety of synthetic pathways. Benzylidene Compound,Benzylidene Derivative,Benzylidene Derivatives,Phenylmethylene Derivative,Phenylmethylene Derivatives,Compound, Benzylidene,Compounds, Benzylidene,Derivative, Benzylidene,Derivative, Phenylmethylene,Derivatives, Benzylidene,Derivatives, Phenylmethylene
D018680 Cholinergic Antagonists Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists. Acetylcholine Antagonist,Acetylcholine Antagonists,Anti-Cholinergic,Anticholinergic,Anticholinergic Agent,Anticholinergic Agents,Cholinergic Receptor Antagonist,Cholinergic-Blocking Agent,Cholinergic-Blocking Agents,Cholinolytic,Cholinolytics,Anti-Cholinergics,Anticholinergics,Cholinergic Antagonist,Cholinergic Receptor Antagonists,Agent, Anticholinergic,Agent, Cholinergic-Blocking,Agents, Anticholinergic,Agents, Cholinergic-Blocking,Antagonist, Acetylcholine,Antagonist, Cholinergic,Antagonist, Cholinergic Receptor,Antagonists, Acetylcholine,Antagonists, Cholinergic,Antagonists, Cholinergic Receptor,Anti Cholinergic,Anti Cholinergics,Cholinergic Blocking Agent,Cholinergic Blocking Agents,Receptor Antagonist, Cholinergic,Receptor Antagonists, Cholinergic

Related Publications

Qiang Nai, and J Michael McIntosh, and Joseph F Margiotta
January 1997, Advances in pharmacology (San Diego, Calif.),
Qiang Nai, and J Michael McIntosh, and Joseph F Margiotta
July 2002, The Journal of physiology,
Qiang Nai, and J Michael McIntosh, and Joseph F Margiotta
October 1996, Neuroscience letters,
Qiang Nai, and J Michael McIntosh, and Joseph F Margiotta
October 2000, Neuropharmacology,
Qiang Nai, and J Michael McIntosh, and Joseph F Margiotta
March 1989, Journal of neurochemistry,
Qiang Nai, and J Michael McIntosh, and Joseph F Margiotta
February 2009, The Journal of biological chemistry,
Qiang Nai, and J Michael McIntosh, and Joseph F Margiotta
May 1995, Annals of the New York Academy of Sciences,
Qiang Nai, and J Michael McIntosh, and Joseph F Margiotta
August 1990, Journal of neurochemistry,
Qiang Nai, and J Michael McIntosh, and Joseph F Margiotta
March 1991, Nature,
Qiang Nai, and J Michael McIntosh, and Joseph F Margiotta
November 1999, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Copied contents to your clipboard!